Navigation Links
John Theurer Cancer Center Announces Positive Results from Revlimid MCL-001(EMERGE) Study Leading to FDA Approval of First Oral Therapy for Refractory Mantle-Cell Lymphoma (MCL) Patients
Date:9/26/2013

HACKENSACK, N.J., Sept. 26, 2013 /PRNewswire/ -- Andre Goy, M.D., M.S., Chairman and Director of John Theurer Cancer Center and Chief of the Lymphoma Program, has just published two important papers in relapsed/refractory mantle-cell lymphoma (MCL) in the Journal of Clinical Oncology and New England Journal of Medicine. MCL is a difficult subtype of non-Hodgkin lymphoma, where patients often become chemoresistant after responding to initial therapy.

Dr. Goy, an international expert in the field, led the lenalidomide global pivotal trial known as MCL-001 or EMERGE trial. Lenalidomide belongs to a category of immunomodulators that is first-in-class approved for lymphoma. This Phase II study showed that lenalidomide induced rapid and prolonged response in patients who were heavily pretreated regardless of the number of their prior regimens and with a median duration of response of more than 16 months. Many of these patients had also been refractory to their last prior therapy. The EMERGE trial results were published in the leading Journal of Clinical Oncology ("Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study" JCO September 2013).

"This trial led to the recent approval by the FDA of lenalidomide as the first oral compound available for that disease addressing a definite unmet need for these patients," said Andre Goy, M.D., M.S., Chairman and Director, and Chief of Lymphoma, John Theurer Cancer Center and Chief Science Officer and Director of Research and Innovation of Regional Cancer Care Associates. "Lenalidomide is only the second drug ever approved for the treatment of mantle-cell lymphoma."

The second study was published in the New England Journal of Medicine a few weeks ago in collaboration
'/>"/>

SOURCE John Theurer Cancer Center
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Revolutionary Natural Sunscreen That Can Reverse Wrinkles, Fine Lines, Sagging Skin, Laugh Lines And Potentially Reverse Cancer Cell Formation With Anti-Aging And Anti-Cancer Forming Natural Ingredients Now Available From Rejuve MD
2. New Survey Reveals U.S. Men with Advanced Prostate Cancer Worry More about Burdening Family and Friends Than Dying
3. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
4. Laser-Proton Therapy Working Group Takes Second Look at Ways to Lower Cost of Advanced Cancer Treatment
5. APPLIED INTEGRIN SCIENCES, INC. LAUNCHES CROWDFUNDING CAMPAIGN TO RAISE FUNDS FOR ITS CANCER DRUG DEVELOPMENT PROGRAM
6. In Turkey, the Use of Targeted Therapies Will Continue to Sustain the Colorectal Cancer Drug Market
7. According to Surveyed U.S. Oncologists, Zytiga is the Patient-Share Leader in First-Line Metastatic Castrate-Resistant Prostate Cancer
8. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
9. K94 Discoveries, Inc. Announces Seed Financing To Advance Targeted Drug Conjugates To Treat Pancreatic And Other Cancers
10. Chrysalis BioTherapeutics, Inc., Receives $1.5m from the National Cancer Institute to Mitigate Radiotherapy-Induced Brain Tissue Damage
11. Study Suggests that a Single Session of Stereotactic Body Radiation Therapy (Lung Radiosurgery) is a Promising Approach for Treating Inoperable Early-Stage Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015  Pharmacyclics, Inc. (NASDAQ: PCYC ... published in the Proceedings of the National ... showed when ibrutinib (IMBRUVICA ® ) was combined ... of tumor growth was enhanced suggesting a greater ... cancers and solid tumors with the combination. IMBRUVICA ...
(Date:2/27/2015)... CARLSBAD, Calif., Feb. 27, 2015 Isis Pharmaceuticals, ... significantly outperformed both its pro forma net operating loss ... in a strong financial position.  Isis, significantly improved financial ... than $230 million in payments the Company received from ... for 2014 was a nearly 60% improvement over its ...
(Date:2/27/2015)... 2015   Synageva BioPharma Corp. (Synageva) ... developing therapeutic products for rare diseases, joins the ... Organisation for Rare Diseases™ (EURORDIS™), The Global Genes ... Rare Disease Day. On the last ... and other participants conduct special events to raise ...
Breaking Medicine Technology:In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6
... trial show those treated with,Prexige experienced significantly smaller ... Many patients with osteoarthritis also have high blood,pressure; ... risk[2],[3] , * Prexige approved in more than ... use in osteoarthritis patients , BASEL, Switzerland, June ...
... an AI Over Tamoxifen in,a Single Trial ... of the entire,population of a single trial has ... significantly improved by switching from,tamoxifen to anastrozole (Arimidex). ... published online in The,Journal of Clinical Oncology, confirms ...
Cached Medicine Technology:Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 6Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 2Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 3Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 4Anastrozole (Arimidex) Improves Overall Survival in Postmenopausal,Women with Early Breast Cancer Receiving Treatment with Tamoxifen 5
(Date:2/27/2015)... In New York City, a Brooklyn dentist is ... care from his Sheepshead Bay­neighborhood practice. Dr. Leonard ... Heart, and will be hosting a charity event on ... are in need of fillings, extractions, or professional dental ... high­quality service of Dr. Umanoff's practice on the Dentistry ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The federal ... ) that allege use of the statin medication can ... has issued a new order pertaining discovery in the ... Bernstein Liebhard LLP comments. The Order, which was issued ... on February 25th, directs the parties to schedule certain ...
(Date:2/27/2015)... 27, 2015 According to court documents, ... on June 25, 2013 and underwent a procedure during ... her mouth. Because the duodenoscope allegedly had not ... antibiotic-resistant “superbug” carbapenem-resistant Enterobacteriaceae (CRE). , A ... Cook County on behalf of Ms. Pirolli alleging that ...
(Date:2/27/2015)... Daytona Beach, FL (PRWEB) February 27, 2015 ... marketing medical companies, devices and pharmaceuticals, Benedict Advertising ... FL as its newest client. The company’s patented ... is a pain-free, no-stress method of sedation. , ... taking medical patient comfort to a new level, ...
(Date:2/27/2015)... The Dawn Greene Hospice, a 10-bed facility located on the ... Upper East Side, was officially dedicated and blessed at a ... Michael Cardinal Dolan. , Thomas J. Fahey, Jr., MD, chairman ... of the ArchCare Board of Trustees, presided over the event ... of MMW, and Christina McInerney, president and CEO of The ...
Breaking Medicine News(10 mins):Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 2Health News:Dr. Umanoff Unites with Dentistry from the Heart to Provide Community with Charitable Dental Care 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2Health News:Benedict Advertising & Marketing Signs Sedation Systems 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3
... Introduced to Nearly 2,500 ... Camps Nationwide, ATLANTA, March ... announced today that it has teamed up with the,American Camp Association(R) (ACA), ... development and enrich the,lives of children through the camp experience., "Our ...
... G.,Rendell today proclaimed March 10-14 as Older Pennsylvanians, Nutrition,Awareness ... how simple,dietary changes can help to improve their health ... major factor in staying healthy, and that,s,especially true for ... nation for the percentage of seniors and their care ...
... Tefen USA Projects Health Care,Spending May More Than Double as Hospital Capacity ... ... The approaching onslaught of over 70,million aging baby boomers could overwhelm ... a new study, "Will the,Boom Bust Health Care?," by management consulting firm ...
... March,29 at 8:00 am, the Bowen Foundation for Autism ... Annapolis to raise money to fight autism. For a,registration ... 5K,waterfront course complete with activities for the whole family ... event go toward the Bowen,Foundation, an organization created to ...
... have shown that just listening to a cell phone while ... commit some of the same types of driving errors that ... cell phones, including dialing and texting, has long been a ... the first time, used brain imaging to document that listening ...
... and young drivers are prime reasons why, study finds , , ... in automobiles that crash are more likely to die than ... is being driven by a young, inexperienced driver, a new ... passengers aged 8 to 17. From 2000 to 2005, 9,807 ...
Cached Medicine News:Health News:White Hat Brands, American Camp Association Launch Partnership to Advance Children's Wellness 2Health News:Governor Rendell Proclaims Older Pennsylvanians' Nutrition Awareness Week 2Health News:Governor Rendell Proclaims Older Pennsylvanians' Nutrition Awareness Week 3Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 2Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 3Health News:New Study: Aging Baby Boomers Could Overwhelm U.S. Health Care System by 2017, Unless Decisive Action Is Taken 4Health News:Inaugural Bowen Foundation Run/Walk to Fight Autism in Maryland Set for Saturday, March 29 2Health News:Carnegie Mellon study shows just listening to cell phones significantly impairs drivers 2Health News:Carnegie Mellon study shows just listening to cell phones significantly impairs drivers 3Health News:Teen Passengers at Higher Death Risk in Car Crashes 2Health News:Teen Passengers at Higher Death Risk in Car Crashes 3
... a broad selection of tip ... wide variety of ophthalmic procedures. ... packaged sterile, complete with a ... in the "off " position ...
... Accu-Temp Cauteries provide a broad ... cauterization in a wide variety ... use cautery is packaged sterile, ... to lock switch in the ...
... Cauteries provide a broad selection of ... wide variety of ophthalmic procedures. Each ... complete with a safety cap to ... position when not in use, and ...
... provide a broad selection of tip ... variety of ophthalmic procedures. Each single ... with a safety cap to lock ... when not in use, and carries ...
Medicine Products: